Date: 2015-01-01
Type of information: Series B financing round
Company: Orphazyme (Denmark)
Investors: Kurma Partners (France) Idinvest Partners (France) Novo A/S (Denmark) Sunstone Capital (Denmark) Aescap Venture (The Netherlands)
Amount: € 20 million
Funding type: series B financing round
Planned used: Orphazyme ApS develops novel therapeutics for the treatment of rare and genetic diseases. The company was founded on research on the therapeutic potential of the cellular heat shock response and is now developing a family of well-tolerated small molecule inducers of heat shock proteins as treatments for lysosomal storage diseases and other neurodegenerative diseases. A clinical Phase 2 study in Niemann-Pick Disease type C, a detrimental lysosomal storage disease, is currently in preparation.
Others: * On January 1, 2015, Orphazyme announced the successful completion of a 20 million Euro Series B financing round. Kurma Partners and Idinvest Partners join the existing investor syndicate of Novo A/S, Sunstone Capital and Aescap Venture.
The Series B round was led by Kurma Partners, and Remi Droller, Managing Partner, will join the Board of Orphazyme in conjunction with the closing of the Series B round.
Therapeutic area: Genetic diseases - Rare diseases
